

JOHNSON WINTER & SLATTERY
L A W Y E R S

Facsimile Transmission

To: Market Announcements Office - Australian Securities Exchange

Fax Number: 1300 135 638

From: Byron Koster, Johnson Winter & Slattery

Phone: +61 2 8274 9550

Fax Number: +61 8 8239 7100

Date: 30 July 2015

Our Ref: B1678

Total pages in this transmission: 5 (including this page)

If you do not receive all pages please contact us immediately

This facsimile transmission is a confidential communication to the person named above. It may be subject to legal professional privilege or otherwise protected under applicable laws. The use of this transmission or the information and data comprising it by any person other than the named addressee is prohibited. If you have received this transmission but you are not the named addressee would you please telephone us on (08) 8239 7111, and forward the document produced as a result of this transmission by secure courier. Your costs of doing so will be refunded.

www.jws.com.au

Liability limited by a scheme approved under Professional Standards Legislation (Australia-wide except in Tasmania)

JOHNSON WINTER & SLATTERY
L A W Y E R S

Partner: Byron Koster +61 2 8274 9550
Email: byron.koster@jws.com.au
Senior Associate: Naomi Philp +61 2 8247 9633
Email: naomi.philp@jws.com.au
Our Ref: B1678

30 July 2015

BY FAX: 1300 135 638

Market Announcements Office
Australian Securities Exchange

Dear Sir/Madam

Clinuvel Pharmaceuticals Limited (ASX:CUV)
Form 605: Notice of ceasing to be a substantial holder

Attached is a Form 605: Notice of ceasing to be a substantial holder for Retrophin, Inc. and its controlled entities.

Yours faithfully,

Johnson Winter & Slattery

Byron Koster
Partner

Level 25, 20 Bond Street
SYDNEY NSW 2000
T +61 2 8274 9555 | F +61 2 8274 9500

www.jws.com.au

SYDNEY | PERTH | MELBOURNE | BRISBANE | ADELAIDE

Liability limited by a scheme approved under Professional Standards Legislation (Australia-wide except in Tasmania)

Form 605**Corporations Act 2001
Section 671B****Notice of ceasing to be a substantial holder****To** Company Name/Scheme CLINUVEL PHARMACEUTICALS LIMITED (ASX:CUV)ACN/ARSN 089 644 119**1. Details of substantial holder (1)**Name Retrophin, Inc. and its controlled entities listed in Annexure A.ACN/ARSN (if applicable) N/AThe holder ceased to be a substantial holder on 28 / 07 / 2015The previous notice was given to the company on 12 / 09 / 2014The previous notice was dated 12 / 09 / 2014**2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's voted affected
28/07/2015	Retrophin, Inc.	Sale of ordinary shares	\$2.40	1,000,000 ordinary shares	1,000,000
28/07/2015	Retrophin, Inc.	Sale of ordinary shares	\$2.40	1,627,162 ordinary shares	1,627,162

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
See Annexure A	See Annexure A

Signatureprint name Byron KosterCapacity: Agentsign here date 30/07/2015

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (6) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Annexure A

This is Annexure A of one page referred to in the Form 605: Notice of ceasing to be a substantial holder
by Retrophin, Inc. and its controlled entities

Signature:**Name:**

Byron Koster

Capacity:

Agent

Date:

30 July 2015

Name	Address
Retrophin, Inc., Retrophin Therapeutics I, Inc. Retrophin Therapeutics II, Inc., Retrophin Pharmaceuticals, Inc., Kyalin Biosciences, Inc., Manchester Pharmaceuticals LLC, RTRX International C.V., Retrophin Therapeutics International, LLC, Retrophin Therapeutics International, Coop, Retrophin International, LLC, Retrophin Therapeutics International I B.V., Retrophin Therapeutics International II B.V.	12255 El Camino Real, Suite 250, San Diego, CA 92130

For personal use only